We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues.
Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease
What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.
Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.
Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.
A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.
Possible benefits and risks:
Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.
NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.
Researchers will monitor participants closely for any side effects throughout the study.

开始日期2025-04-28

申办/合作机构

Metro International Biotech LLC

CTRI/2024/11/077325

/ Not yet recruiting临床4期

To study the effectiveness of Plum 2% Niacinamide & Rice Water Face Wash for skin brightening, hydration and softness - NIL

开始日期2024-12-03

申办/合作机构-

100 项与烟酰胺相关的临床结果

登录后查看更多信息

100 项与烟酰胺相关的转化医学

登录后查看更多信息

100 项与烟酰胺相关的专利（医药）

登录后查看更多信息

19,780

项与烟酰胺相关的文献（医药）

2025-12-01·MOLECULAR BIOLOGY REPORTS

Do human adipose stem cell-derived artificial insulin-producing cells develop tumorigenic characteristics throughout differentiation?

Article

作者: Dayer, Dian ; Jafarinia, Mojtaba ; Salehi Babadi, Parastoo ; Forouzanfar, Mohsen

BACKGROUND:

Artificial insulin-producing cells (IPCs) used to treat diabetes mellitus type 1 (DMT1) are naturally hampered by their carcinogenicity. This in vitro study aimed to examine the carcinogenic potential of IPCs produced by the differentiation of human adipose tissue-derived mesenchymal stem cells (hADSCs).

METHODS AND RESULTS:

hADSCs were transformed into IPCs by administering insulin-transferrin, selenium (ITS), and nicotinamide in a 14-day differentiation protocol. The cells were transfected with 20 μg of pure Pdx1-pIRES recombinant vector on the tenth day of differentiation. The successful transfection was confirmed by Pdx1 overexpression and GFP fluorescence activity. The differentiated cells' capacity to release insulin and glucose-dependent C-peptide was used to evaluate their functionality. Gene expression was assessed using real-time PCR. Meanwhile, protein expression was investigated using western blotting. The transfected cells exhibited fluorescence activity and Pdx1 overexpression. The differentiated IPCs were able to secrete C-peptide and insulin. The artificial IPCs showed significantly reduced Oct4 and Nanog expression. However, the differentiation process induced a noticeable elevation in tPA expression. The artificial IPCs expressed much lower c-MYC expression compared to undifferentiated hADSCs. The differentiated cells exhibited a significant elevation in Glut2, MMP-2, CD24, P16, and P21 expression.

CONCLUSIONS:

The differentiation technique used in this work produced functional beta-like cells devoid of typical markers of stem cells. The synthetic IPCs displayed characteristics of newly generated β-like cells. The artificial IPCs showed no signs of expressing tumor-associated markers. The findings imply that the artificial IPC cells lack tumor characteristics in vitro.

2025-09-01·NEUROPHARMACOLOGY

Sirtuins modulators mitigate hypoxia-induced cell death due to changes in histone 3 acetylation, and mitochondrial function, dynamics, and content

Article

作者: Rosenstock, Tatiana Rosado ; Souza E Silva, Luiz Felipe ; Siena, Amanda ; Yuzawa, Jessica Mayumi

Hypoxia is a key environmental factor linked to neurodevelopmental complications, primarily through its impact on mitochondrial dysfunction. Given that sirtuins regulate mitochondrial and cellular metabolism, we aimed to investigate whether pharmacological modulation of sirtuins could protect neurons from hypoxia-induced mitochondrial dysfunction and cell death. To explore this, primary cortical neurons from male Wistar rats (control) and Spontaneously Hypertensive Rats (a model for neonatal hypoxia and schizophrenia) were exposed to cobalt chloride (CoCl₂) to chemically induce hypoxia. Neurons were also treated with Nicotinamide (50 μM), Resveratrol (0.5 μM), and Sirtinol (5 μM) to modulate sirtuin activity. We first assessed histone deacetylation, cell death, mitochondrial calcium retention capacity, mitochondrial membrane potential, and levels of reactive oxygen species (ROS). In addition, we analysed the expression of genes related to mitochondrial metabolism, dynamics, and biogenesis, as well as high-energy compound levels. Our data indicate that both chemical and neonatal hypoxia caused mitochondrial depolarization, reduced calcium retention, increased ROS levels, and elevated Nfe2l2 expression in primary cortical neurons. Hypoxia also led to increased expression of genes associated with mitochondrial biogenesis and fission, as well as reduced ATP levels and elevated pyruvate and lactate levels. Importantly, treatment with sirtuin modulators enhanced neuron viability, likely by further increasing Nfe2l2 expression and reducing ROS production. These modulators also improved metabolic outcomes, including higher ATP levels, and normalised pyruvate and lactate production, as well as mitochondrial fusion gene expression. Collectively, our findings suggest that sirtuin modulators could mitigate hypoxia-induced damage and may represent a potential therapeutic strategy for managing neurodevelopmental disorders.

2025-09-01·Comparative Biochemistry and Physiology D-Genomics & Proteomics

Dynamic metabolic profiling of sea cucumbers (Apostichopus japonicus) under predation stress

Article

作者: Song, Jian ; Sun, Yongxin ; Wang, Shuo ; Qu, Liang ; Wang, Qingzhi ; Wang, Meng ; Wang, Chong ; Zhao, Chong

The present study utilized non-targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) to investigate the metabolomic responses of sea cucumber (Apostichopus japonicus) juveniles under predation stress induced by sea stars (Asterina pectinifera) at various time points (3 h, 12 h, 72 h, and 96 h). The findings revealed significant temporal changes in the metabolic profiles of the sea cucumber juveniles under predation stress, with 25, 72, 55, and 53 metabolic products exhibiting significantly different expression levels at each time point (positive ion mode, P < 0.05), respectively. Notably, the impact of predation stress was most pronounced at the 12-h mark. Multivariate statistical methods, including principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA), further confirmed distinct clustering of the experimental group away from the control group at each time point, with the most pronounced separation occurring at 12 h, indicating a significant and time-dependent metabolic response to predation stress. Key metabolic pathways associated with predation stress were identified, such as carbon metabolism, pentose phosphate pathway, purine metabolism, riboflavin metabolism, longevity regulation, and antifolate resistance pathways, by integrating variable importance in the projection (VIP), fold change (FC), and P-value. KEGG enrichment analysis highlighted significant expression changes of key metabolites like carbamoyl phosphate, gluconolactone, inosine, 2'-deoxyguanosine, and adenylate in response to predation stress, potentially related to energy metabolism, antioxidant defense, signal transduction, and cellular stress responses. The study provides novel insights into the metabolic adaptability of sea cucumber juveniles to predation stress.

189

项与烟酰胺相关的新闻（医药）

2025-05-22

·梅斯医学

这几种维生素能加速新冠患者康复？Nature子刊：不仅让超一半患者2周内恢复体力，还能调节肠道，缓解后遗症，促进抗体生成

最近，“阳了”这件事又开始在各大社交平台刷屏了。中国疾控中心发布的2025年4月（第14周—18周，3月31日—5月4日）的全国急性呼吸道传染病哨点监测情况显示，我国门急诊中流感样病例的新冠病毒阳性率就从7.5％猛升到16.2％；住院严重急性呼吸道感染病例从3.3％上升至6.3％，翻了近一倍。这一波新冠感染的回潮，让不少人再次感受到新冠病毒的存在感和其带来的危机感。不过，比病毒反弹更令人关注的，是我们能做些什么来更快地恢复健康，减少“长新冠”后遗症的风险。近期，一项来自德国基尔大学的研究[1]为应对新冠提供了新的思路。该研究发表在Nature Metabolism上，结果显示：常见的水溶性维生素B3的一种主要形式——烟酰胺，不仅能够加快轻中度新冠患者的康复速度，还能改善患者的肠道菌群代谢功能。身体“电量”告急，新冠康复为何这么难？还记得刚感染新冠那会儿的感觉吗？浑身乏力、走几步路就像跑完马拉松，哪怕只是下床倒杯水，都像经历一场体力拉锯战。研究者们发现，这种“体力告急”的状态，可能和身体里一种叫做烟酰胺腺嘌呤二核苷酸（NAD⁺）的分子有关。它好比细胞的小电池，是维持能量代谢和免疫功能的关键辅酶。一旦新冠来袭，这些“小电池”会被迅速消耗，导致身体“断电”；而合成NAD⁺的原材料——色氨酸，也容易在感染后被打乱代谢流程；再加上肠道菌群紊乱火上浇油，整个免疫-代谢系统就像一台漏电又失控的机器，难以迅速修复。有了这番机制理解，研究者脑洞一开：既然NAD⁺水平下降这么关键，那我们能不能从源头出发，补一补“电池”原料，让身体恢复供能？他们瞄准了烟酰胺。它是合成NAD⁺的重要前体，也是维生素B3的主要形式之一，早已作为营养素广泛使用。虽然人数不多，但这个差距足以让研究者眼前一亮——也许，真的找对方向了？有了这份“试运行”的信心加持，研究团队决定进一步放大招，启动名为COVit-2的前瞻性、双盲、随机、安慰剂对照的临床试验。烟酰胺干预后，新冠后的“元气”恢复得更快在COVit-2中，研究人员锁定了那些感染新冠后体能明显下降的患者，想看看谁先“回血”。这一结果提示，烟酰胺或许能够帮助更多患者在感染后更快地找回“元气”。不仅如此，在关键的次要终点——日常活动能力的恢复方面，烟酰胺也表现出明显优势。这意味着，烟酰胺不仅促进了体能的恢复，也可能加快了患者“重新动起来”的节奏，帮助他们更早回归正常生活，提升生活质量。另外，烟酰胺对缓解新冠相关咳嗽也显示出一定优势。烟酰胺不仅补“能量”，还能帮助肠道菌群“恢复秩序”接下来，研究人员把目光投向了一个看似不起眼、实则至关重要的战场——肠道。我们的肠道里藏着一支庞大而精密的“微生物部队”，它们不仅负责消化吸收、合成营养物质，还深度参与着免疫反应与代谢调节。于是，研究团队从70位新冠患者身上采集了280份粪便样本，并从中挑选出18位进行了更深入的宏基因组分析，希望看看：烟酰胺是否能帮助这支“部队”恢复秩序、重整旗鼓？分析结果显示，在使用烟酰胺进行干预前后，参与者肠道菌群的丰富度和均衡性（即α-多样性）并没有发生显著变化，整体菌群的“人员配置”看似稳定。然而，当研究人员进一步分析不同受试者之间菌群的差异性（即β-多样性）时，却发现了一个有趣的现象：干预组和安慰剂组在菌群组成上出现了统计学上的显著差异——而这种差异在干预开始前是不存在的。换言之，烟酰胺的加入似乎在“幕后”推动了菌群格局的重组，让肠道生态系统发生了某种有序的变化。并且，这种变化并不是某几种细菌单独造成的，而是整体菌群微妙而协调的调整，反映出烟酰胺对肠道微生态系统的调节是温和而非激进的。那这些菌群到底在“忙”些什么呢？研究人员进一步进行了宏基因组分析，结果发现，在干预第2周时，安慰剂组的菌群格外活跃：它们启动了合成色氨酸、苯丙氨酸、蛋氨酸、赖氨酸等关键氨基酸的路径，还动用了氧化还原和NAD⁺回收机制，像是在加班加点地支援宿主对抗病毒。这种“拼命三郎”般的工作状态，或许正是宿主体内NAD⁺不足所引发的“求援信号”，迫使肠道菌群投入更多资源“自救”。而在烟酰胺组，这种高强度应激反应并不明显，提示烟酰胺可能已经帮宿主缓解了部分压力，让菌群可以“从容不迫”地维持日常运作。看到这里，或许不少人心中都会冒出一个关键问题：烟酰胺能不能减轻新冠“后遗症”？研究人员显然也早就注意到了这一点。在试验结束后的第6个月，他们设置了一个量化指标——PCS评分系统，来评估参与者是否出现了新冠后遗症，以及这些症状的严重程度。这个评分系统的满分是59分，得分越高，代表“后遗症”越严重。整体来看，大多数参与者的PCS评分都偏低，说明本次试验中新冠症状总体较轻。也就是说，烟酰胺可能在有早期疗效反应的高风险人群中，有效减轻了后遗症的严重程度。而在临床研究中，疗效固然重要，但安全性评估同样是绕不过去的一道“关卡”。安全性分析显示，烟酰胺在整体安全性上与安慰剂相当，且未发现烟酰胺会增加严重不良事件或死亡的风险。研究人员进一步指出，从潜在机制角度看，烟酰胺的干预作用可能通过调节肠道微生物群，进而改善机体的代谢状态和免疫功能。这种肠道微生态的变化，或许不仅限于局部效应，还可能通过“肠–肺轴”这一关键通路，对呼吸道免疫产生远程调节作用，从而增强机体对新冠病毒的整体应答能力，促进病程恢复。总体而言，这项研究不仅为烟酰胺用于新冠干预提供了临床层面的支持，也将代谢干预手段与免疫调节、微生态平衡有效结合，为新冠治疗开辟了一条区别于传统抗病毒思路的“代谢支持”新路径。维生素C+锌、维生素D也能出“奇迹”除了上述讨论的维生素B3形式——烟酰胺，还有研究发现，其他几种常见补剂同样有助于加快新冠康复，特别是在提升抗体水平方面展现出积极效果。其中，一项由新加坡国立大学团队发表在Clinical and Translational Medicine的研究[2]发现，新冠感染后，同时服用维生素C+锌，可以让“阳康”患者尽可能提升中和抗体水平，减少重复感染几率。研究人员特别指出，在无症状感染者中，有一半以上个体的中和抗体本就生成欠佳，与其他干预措施相比，那些接受锌+维生素C的人被发现会产生更大的抗体反应，为防止重复感染提供帮助。这意味着，高峰期“中招”的“阳康”们在面对后续的感染高峰时，可以通过适量补充维C+锌增强体内抗体水平。此外，维生素D的作用也不容忽视。看来，日常防疫，我们除了口罩、消毒，或许也能让这些维生素来点“幕后助攻”，甚至感染后恢复起来都能快人一步~仍需指出的是，研究[1]由于招募期间的病毒变种限制和试验的远程性质；研究[2]是在特定男性人群中进行的，使用的是特定剂量和组合的锌和维生素C；研究[3]不能直接推断因果关系，均对研究结果的外推性有一定影响。参考资料：[1]Schreiber, S., Waetzig, G.H., López-Agudelo, V.A.et al. Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01290-1[2]Quek AML, Ooi DSQ, Teng O, Chan CY, Ng GJL, Ng MY, Yee S, Cheong EW, Weng R, Cook AR, Hartman M, Angeli V, Tambyah PA, Seet RCS. Zinc and vitamin C intake increases spike and neutralising antibody production following SARS-CoV-2 infection. Clin Transl Med. 2022 Feb;12(2):e731. doi: 10.1002/ctm2.731. PMID: 35184404; PMCID: PMC8858613.[3]Gibbons, J.B., Norton, E.C., McCullough, J.S.et al. Association between vitamin D supplementation and COVID-19 infection and mortality. Sci Rep 12, 19397 (2022). https://doi.org/10.1038/s41598-022-24053-4撰文 | 木白编辑 | 木白●震撼！外资医院院长：我需要有真技术的医生，不需要头衔、不需要科研！公立三甲医生：手术再漂亮不如别人一篇文章！公立和外资有啥不同?●中国痴呆发病率飙升300%！而久坐易痴呆？Science：缺氧才是大脑“常态”，它“助攻”痴呆发展，但运动可使缺氧负担减轻52%● 热议！99年女医生晚上搞副业收破烂，挣的比在医院多！和送外卖比较时薪、和保姆比较日薪，当医生完败！真想搞副业挣钱，医生该干什么？版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床结果

2025-05-21

·EINPresswire

AOB Pharma reveals new metabolomic insights of B244, suggesting investigation of potential new avenues for treatment

AOB Pharma reveals new insights via metabolomic analysis of B244, supporting clinical readouts & suggesting investigation of potential new avenues for treatment CAMBRIDGE, MA, UNITED STATES, May 21, 2025 / EINPresswire.com / -- AOB Pharma reveals new mechanistic insights via metabolomic analysis of B244, supporting clinical readouts and suggesting investigation of potential new avenues for treatment • B244 produces numerous skin-beneficial metabolites including ceramides, retinoids, tocopherol, and niacinamide • The presence of these anti-inflammatory and skin-beneficial compounds suggest additional ways that B244 can improve atopic dermatitis and other inflammatory skin diseases • Mining of additional metabolomic data may additionally suggest new indications for which B244 can be used • Select data will be presented by Dan Brownell, AOBiome’s Senior Director of R&D, at the Dermatology Drug Development Summit Europe, taking place in Berlin May 27-28, 2025 CAMBRIDGE, MA, May 21, 2025. AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions, shares new data showing that B244, their lead asset, secretes a suite of anti-inflammatory and beneficial skin metabolites. Metabolomic analysis of B244 has revealed the production of various ceramides, retinoids, tocopherol, niacinamide, and many other compounds critical for skin health. These compounds, in addition to the previously understood mechanisms of action, further highlight the multifactorial benefits of B244 for the potential treatment of additional inflammatory diseases. Ceramides are essential lipids that help maintain the skin's natural barrier, which is often compromised in people with atopic dermatitis. By replenishing ceramide levels, the skin can maintain moisture, reduce dryness, and protect the skin from irritants and allergens. This strengthens the skin’s defense, soothes inflammation, and reduces flare-ups, making ceramides a tool in the maintenance of skin health. Other metabolites produced by B244 have similar potential benefits that justify investigation for use in treatment, including reducing inflammation, antioxidant effects, improvement in skin appearance associated with various skin disorders. “B244 is clearly more than simply a probiotic: these active metabolites have the potential to support the skin in multiple ways simultaneously, unlike any product currently in the marketplace. There is tremendous potential here to revolutionize our understanding of the role of bacteria in skin health and resilience” says Peter Lio, MD, Founding Partner, Medical Dermatology Associates of Chicago. AOBiome is currently preparing to initiate a global Phase 3 study to evaluate B244 for the treatment of mild-to-moderate Atopic Dermatitis and associated moderate-to-severe itch, following the successful completion of a 547 patient Phase 2b study. In addition to the previously understood mechanisms of B244, these new metabolomic insights further suggest the range of improvements of AD symptoms seen clinically. “From an evolutionary standpoint, this further highlights the potential need for ammonia oxidizing bacteria for not only maintaining healthy skin, but treating inflammatory conditions that we did not evolve to have” says President and CEO Todd Krueger. About B244 AOBiome’s B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. B244 has been observed to be safe and well-tolerated in clinical studies to date. Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31. See full article at: https://www.nature.com/articles/s41598-021-93299-1 . About AOB Pharma, Inc. AOB Pharma, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing topical therapeutics for inflammatory conditions. AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. Learn more at AOBiome.com . For Media Inquiries: Jim Hoffman AOBiome Therapeutics +1 617-639-9980 Press@aobiome.com Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床2期微生物疗法

2025-05-21

·生物世界

Nature子刊：烟酰胺可加速新冠患者康复

撰文丨王聪编辑丨王多鱼排版丨水成文COVID-19 仍是全球疾病负担的重头，即便在疫情后期，也造成了相当大的劳动生产力损失。呼吸系统症状往往与体能急剧下降以及无法进行正常活动相关联。尽管由于疫苗接种和抗病毒治疗，总体死亡率已大幅降低，但目前仍迫切需要一种有效、广泛且能缓解症状的干预措施。近日，Nature 子刊 Nature Metabolism 上发表了一篇题为：Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19 的研究论文。该研究表明，烟酰胺（Nicotinamide）可加速轻度和中度 COVID-19 患者的身体功能康复，并调控 COVID-19 相关的肠道菌群变化。烟酰胺（Nicotinamide）是生成氧化型烟酰胺腺嘌呤二核苷酸（NAD+）所必需的，而 NAD+ 是细胞能量代谢中的关键辅酶。在病毒感染期间（尤其是新冠病毒感染期间），NAD+ 的可用量会减少。NAD+ 可以通过从头合成途径由必需氨基酸色氨酸生成，也可通过前体物质烟酸、烟酰胺核苷或烟酰胺来生成。值得注意的是，在新冠病毒（SARS-CoV-2）感染引发的急性炎症期间，色氨酸分解代谢增强，表现为犬尿氨酸水平升高，而犬尿氨酸是从头合成 NAD+ 途径中的关键中间体。色氨酸的降解源于色氨酸分解酶活性增强，这不仅与 COVID-19 的严重程度有关，而且在其他感染性疾病（包括细菌性肺炎、病毒感染）中也有观察到。此外，色氨酸的吸收依赖于肠道上皮细胞中 ACE2 的存在，而 ACE2 也是新冠病毒（SARS-CoV-2）入侵人类细胞的受体。COVID-19 与肠道微生物群的紊乱密切相关，其特征是微生物多样性降低以及有益菌种减少。这些失衡与炎症加剧和免疫失调有关，并被认为会导致更严重的疾病结局。该团队之前的研究表明，色氨酸有助于维持肠道微生物群的稳态，并且在结肠炎模型中，补充烟酰胺会产生强烈的、微生物群依赖的抗炎作用。在小鼠体内，肠道靶向补充烟酰胺表现出剂量依赖性的抗炎作用，其效果优于全身补充。鉴于色氨酸的代谢异常与新冠病毒（SARS-CoV-2）感染者的肠道微生物群失调有关，局部使用烟酰胺可能有助于调节肠道微生物群，改善感染的预后，同时还能发挥其全身抗病毒的益处。在这项新研究中，研究团队开发了一种药物用的 pH 值依赖型基质片剂配方，其成分均获准用于食品和药品。这种配方旨在使烟酰胺能够在小肠下部和结肠释放，确保烟酰胺的全身供应，并靶向肠道更远端的部分，包括肠道微生物群。该研究报告了两项随机对照试验的结果，一项规模较小的试点实验（COVit-1）使用的是常规烟酰胺片剂，以及一项规模较大的 COVit-2 试验，该试验将常规烟酰胺片剂与肠道靶向烟酰胺片剂结合使用，对象为在新冠病毒核酸检测呈阳性后 7 天内的门诊患者。在 COVit-2 试验中，研究团队对 900 名经核酸检测确诊的有症状 COVID-19 患者进行了为期 4 周的新型烟酰胺制剂（1000毫克）干预评估。在具有重症风险的主要分析人群中，接受烟酰胺治疗组 57.6% 的受试者在第 2 周即从体能下降中恢复，而安慰剂组恢复比例为 42.6%。烟酰胺还显著促进患者恢复正常活动能力。肠道宏基因组特征变化与临床疗效具有一致性，提示烟酰胺可调节新冠病毒（SARS-CoV-2）感染相关的粪便微生物群改变。在治疗后 6 个月的随访中，急性期对烟酰胺治疗有反应者出现新冠后遗症的比例低于安慰剂组。整个研究过程中未发现相关安全性风险。COVit-2 试验设计烟酰胺治疗促进 COVID-19 患者从体能下降中恢复总体结果表明，烟酰胺可加速轻度和中度 COVID-19 患者的身体功能康复，并调控 COVID-19 相关的肠道菌群变化。论文链接：https://www.nature.com/articles/s42255-025-01290-1设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

寡核苷酸临床研究

100 项与烟酰胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00036	烟酰胺	A11HA01	DB02701

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心律失常	中国	山西泰盛制药有限公司	2006-03-10
冠心病	中国	山西泰盛制药有限公司	2006-03-10
心肌炎	中国	山西泰盛制药有限公司	2006-03-10
维生素B缺乏症	中国	华润双鹤药业股份有限公司	1996-01-01
糙皮病	日本	Catalent Japan KK	1961-10-27
寻常痤疮	-	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床2期	德国	MEDICE Arzneimittel Pütter GmbH & Co. KG	2010-08-01
高磷血症	临床2期	德国	MEDICE Arzneimittel Pütter GmbH & Co. KG	2010-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03061474 (NEAT, Pubmed \| Alzheimers Res Ther)	临床2期	阿尔茨海默症 pTau231	47	Nicotinamide 1500 mg PO BID	襯願鑰膚積憲觸齋蓋膚(鹹糧鏇夢製齋獵網齋鏇) = 鹽餘繭繭獵鬱鹽製膚繭餘夢願鏇窪築鬱廠範淵 (積齋齋鹽積遞鏇艱壓壓 ) 更多	不佳	2025-03-11
				Placebo	餘製齋膚衊餘鹹獵醖憲(顧壓憲廠範襯壓製製窪) = 齋壓構憲繭獵簾襯襯簾廠構鹽鏇範齋襯網淵壓 (鑰積糧壓齋觸膚獵壓艱 )
NCT02416739 (Pubmed) 人工标引	临床2期	EGFR突变肺癌 EGFR Mutation	110	Nicotinamide	觸膚蓋選繭鬱繭網窪積(築憲衊糧網襯糧醖簾顧) = 鹹構艱遞遞憲窪鏇獵淵顧膚鹹壓憲獵襯襯鹽鹹 (淵簾製餘積鬱製願鹽夢, 10.4 ~ 18.3) 更多	积极	2024-04-09
				Placebo	觸膚蓋選繭鬱繭網窪積(築憲衊糧網襯糧醖簾顧) = 製襯淵襯構糧淵鑰鑰衊顧膚鹹壓憲獵襯襯鹽鹹 (淵簾製餘積鬱製願鹽夢, 9.0 ~ 13.2) 更多
NCT02416739 (AACR2024) 人工标引	临床2期	EGFR突变肺癌 EGFR Mutation	110	Nicotinamide	製築窪艱築築構餘餘遞(製憲憲願願餘顧範築憲) = 簾窪鬱鬱窪選醖構壓窪壓觸餘鹽簾餘膚鏇簾餘 (範齋衊廠鑰窪鏇構憲鏇, 10.4 ~ 18.3) 更多	积极	2024-04-05
				Placebo	製築窪艱築築構餘餘遞(製憲憲願願餘顧範築憲) = 齋選網鬱艱積鏇艱鏇願壓觸餘鹽簾餘膚鏇簾餘 (範齋衊廠鑰窪鏇構憲鏇, 9.0 ~ 13.2) 更多
NCT03136705 (CTgov)	临床1期	-	39	Lanthanum Carbonate+Nicotinamide (Lanthanum + Nicotinamide)	蓋鏇積襯憲願餘廠廠醖(鹹蓋繭膚遞蓋憲鹽衊窪) = 製糧鹽艱願繭餘夢範積蓋簾遞積淵鬱夢齋鬱繭 (鑰鹽鬱齋簾夢醖遞鬱鑰, 鹽衊艱襯窪範膚鹽鏇願 ~ 壓構觸淵醖糧觸製遞築) 更多	-	2024-02-23
				Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo)	蓋鏇積襯憲願餘廠廠醖(鹹蓋繭膚遞蓋憲鹽衊窪) = 糧構艱構簾餘鹹艱襯網蓋簾遞積淵鬱夢齋鬱繭 (鑰鹽鬱齋簾夢醖遞鬱鑰, 築網製築壓繭鹹夢鬱顧 ~ 網淵憲餘顧淵衊製夢網) 更多
NCT03061474 (NEAT, CTgov)	临床2期	阿尔茨海默症 \| 轻度认知障碍	46	Nicotinamide (Nicotinamide)	鬱築憲顧鏇製淵繭遞醖(觸衊廠網夢鬱膚鏇遞鏇) = 衊製簾夢襯夢襯範鹹餘網網選窪窪製夢願襯選 (衊製觸鏇憲夢範壓積獵, 14.46) 更多	-	2023-10-17
				Placebo Comparator (Placebo)	鬱築憲顧鏇製淵繭遞醖(觸衊廠網夢鬱膚鏇遞鏇) = 鑰積艱糧鑰選繭鬱蓋淵網網選窪窪製夢願襯選 (衊製觸鏇憲夢範壓積獵, 10.55) 更多
WCD2023	N/A	-	-	High broad spectrum sunscreen containing Nicotinamide and Panthenol	襯構廠願顧壓簾築蓋築(壓顧襯範範廠廠艱窪壓) = 衊膚糧餘製鹹願鬱選廠積構鬱顧構餘窪網壓願 (簾遞壓憲蓋艱構簾壓繭 ) 更多	积极	2023-07-03
NCT03419364 (CTgov)	临床2期	先兆子痫	23	nicotinamide (Nicotinamide - Pre-eclampsia)	夢簾蓋醖範選淵繭餘膚(範夢構夢憲鑰鹽鹹獵壓) = 衊簾積鏇鏇製顧獵憲願積築淵範觸窪願憲鹹廠 (淵製醖廠願鏇網窪淵築, 9) 更多	-	2022-09-08
				nicotinamide (Nicotinamide - Healthy Pregnant)	夢簾蓋醖範選淵繭餘膚(範夢構夢憲鑰鹽鹹獵壓) = 願膚簾淵製簾齋網壓構積築淵範觸窪願憲鹹廠 (淵製醖廠願鏇網窪淵築, 9) 更多
EADV2022	N/A	光化性角化病 p21 positive \| DIMTIM \| p53 ... 更多	12	High broad spectrum UVB-UVA sunscreen containing Nicotinamide and Panthenol	築齋蓋遞網鹽構襯願餘(鬱鏇構糧積積襯艱積願) = 餘願獵顧鏇願製繭糧夢糧淵觸簾觸餘醖艱醖觸 (壓夢鏇構鹽鬱鬱鹽廠鹹 ) 更多	积极	2022-09-07
NCT02258074 (COMBINE TRIAL \| COMBINE \| CKD Optimal Management with Binders and Nicotinamide (COMBINE), CTgov)	临床2期	慢性肾病	205	Lanthanum Carbonate+Nicotinamide (Lanthanum Carbonate + Nicotinamide)	壓製餘淵願窪衊觸膚鏇(膚糧齋選襯構廠遞蓋遞) = 獵觸選淵憲鑰淵齋蓋蓋憲鬱艱醖積齋鹽範鹹鏇 (遞鬱艱獵獵鹽鹹醖鹹鑰, 夢觸壓壓簾觸網製淵構 ~ 鬱構廠鏇壓鑰範鹹鏇觸) 更多	-	2021-07-30
				Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo)	壓製餘淵願窪衊觸膚鏇(膚糧齋選襯構廠遞蓋遞) = 簾網鏇壓築鹹簾壓膚網憲鬱艱醖積齋鹽範鹹鏇 (遞鬱艱獵獵鹽鹹醖鹹鑰, 艱齋觸襯積積膚選鏇選 ~ 築艱觸衊醖膚觸蓋鹽廠) 更多
R21 (DK104086) (ASN2020)	N/A	常染色体显性多囊肾病 acetylated p53 \| total p53 protein \| serum creatinine ... 更多	-	Niacinamide 30 mg/kg	選襯獵製鹽衊築鏇鏇衊(選構鹽繭餘壓窪鬱壓憲) = 顧膚遞蓋夢積繭襯衊糧糧遞壓衊範膚鑰範鹹膚 (構糧窪構選醖襯衊艱鏇 ) 更多	不佳	2020-10-19
				Placebo	鏇淵積構膚憲糧積壓鑰(網構夢醖製淵繭鏇鑰顧) = 艱範積憲糧淵糧衊艱製廠夢鹽簾顧壓網鹽願夢 (蓋窪鹽齋選鹹鏇廠糧鬱 )